38 results
Page 2 of 2
8-K
jv2t2a uliw0
19 Feb 21
Y-mAbs Announces Proposed Public Offering of Common Stock
6:01am
424B5
cfj fadm831w
18 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
10pb g67q7ellx8
17 Feb 21
Prospectus supplement for primary offering
6:02am
8-K
EX-99.1
tvkorxkrnubp9m4
4 Dec 20
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
9:09am
8-K
EX-1.1
5lidd39zzlmeucsod5p1
31 Oct 19
Y-mAbs Announces Pricing of Public Offering of Common Stock
12:00am
DEF 14A
6wr31tnf
30 Apr 19
Definitive proxy
3:50pm
10-K
4x4g0cp34qsphwh6o43
22 Mar 19
Annual report
4:02pm
8-K
1rywbjl
12 Mar 19
Regulation FD Disclosure
7:00am
10-Q
5z7b b2d0ai
13 Nov 18
Quarterly report
9:28am
424B4
wifxplvgn vglf2n3vx
21 Sep 18
Prospectus supplement with pricing info
7:33pm
DRS/A
8snxmi6cnedbcbq3qcl
8 Jun 18
Draft registration statement (amended)
12:00am